Small molecule · Inhibitor · developed by Tarsus
Lotilaner is a small molecule that inhibits gamma-aminobutyric acid (GABA)-gated chloride channels in mites, causing paralysis and death of the parasite. It is an ectoparasiticide studied in ocular rosacea.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 10, 2024). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07443202 | Phase 2 | Ocular Rosacea | Enrolling by invitation | TARS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ocular Rosacea
Updated Nov 1, 2026. Something wrong or missing? Report it on the TARS page.
See TARS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TARS catalysts and pipeline →